MedTrace Logo

Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients

NCT04140201 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-01-18

No results posted yet for this study

Summary

The investigator study evaluate the effect of different lipid lowering agents on the progression of diabetic retinopathy and other reduction of cardiovascular risk of diabetic patients

Conditions

Interventions

DRUG

Simvastatin 40mg

Drugs that lower lipid level

DRUG

Fenofibrate 200mg

Drugs that lower lipid levels

DRUG

Omega 3 fatty acid

Drugs that lower lipid levels

Sponsors & Collaborators

  • Alaa Hassan ElBaz

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-29
Primary Completion
2020-06-30
Completion
2020-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04140201 on ClinicalTrials.gov